Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: A prospective study

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 7, 2013, Pages 798-805

  Papastergiou, Vasilios ^a   Stampori, Maria ^a   Lisgos, Phillipos ^a   Pselas, Crisostomos ^a   Prodromidou, Kleopatra ^a   Karatapanis, Stylianos ^a  

^a General Hospital of Rhodes   (Greece)

Author keywords

Aspartate aminotransferase to platelet ratio index; chronic hepatitis C; follow up; hepatocellular carcinoma; pegylated interferon; sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE;

ADULT; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84879939651     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835eb8bf     Document Type: Article

References (41)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Dienstag JL, Mc Hutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-264, quiz 14-17.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875-881.
5. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135:821-829.
6. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5 year follow-up of 150 patients. Hepatology 2009; 49:729-738.
7. Poynard T, Mc Hutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liverfibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
8. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579-587.
9. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, Pianko S. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13:311-315.
10. Khokhar N. Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin. J Gastroenterol Hepatol 2004; 19:471-472.
11. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53:1504-1508.
12. Yamaura T, Matsumoto A, Rokuhara A, Ichijo T, Tanaka E, Hanazaki K, et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J Gastroenterol Hepatol 2002; 17:1229-1235.
13. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12:5532-5535.
14. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27:186-191.
15. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40:148-156.
16. Carreno V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006; 12:6922-6925.
17. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31:1519-1524.
18. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
19. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological responseto pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31:502-508.
20. Trapero-Marugan M, Mendoza J, Chaparro M, Gonzalez-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17:493-498.
21. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-844.
22. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther 2009; 30:477-486.
23. Ciancio A, Smedile A, Giordanino C, Colletta C, Croce G, Pozzi M, et al. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol 2006; 101:1811-1816.
24. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50:1-3.
25. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726-736.
26. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
27. Karatapanis S, Tsoplou P, Papastergiou V, Vasiageorgi A, Stampori M, Saitis I, et al. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 2012; 84:223-228.
28. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10 Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28:1121-1127.
29. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-termfollow-up ofchronic hepatitis C patientswith sustained virological response to alpha-interferon. J Hepatol 1999; 30:783-787.
30. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122:1525-1528.
31. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40:688-696.
32. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14:556-563.
33. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38:493-502.
34. Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006; 44:83-87.
35. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524.
36. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55:569-578.
37. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010; 59:861-866.
38. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (Fibro Scan): a prospective study. Gut 2006; 55:403-408.
39. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25:684-688.
40. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J Viral Hepat 2011; 19: e97-e104.
41. Ramos Paesa C, Marcilla F, Lopez G, Hueso E, Pascual A, Aguirre JM. Valuation of APRI and Forns models for non-invasive diagnosis of fibrosis in patients with hepatitis C in coinfected and non-coinfected with HIV. An Med Interna 2007; 24:369-374.